Group 1 - The board of directors of Tianshui Zhongxing Mushroom Industry Technology Co., Ltd. held its 14th meeting on August 15, 2025, with all 9 directors present [1] - The board approved the proposal for the company's 2025 semi-annual report with a unanimous vote of 9 in favor [2] - The board also approved the proposal to renew the company's auditing firm for the 2025 fiscal year, pending approval from the upcoming shareholders' meeting [2][3] Group 2 - The board approved a proposal to amend the company's business scope and revise the articles of association, which will also require approval from the shareholders' meeting [3][4] - The company will no longer have a supervisory board following the approval of the revised articles of association [3] - The board proposed to adjust the company's organizational structure, which will also be submitted for shareholder approval [4][7] Group 3 - The board approved several governance system revisions and the establishment of new management systems to enhance operational compliance [6][7] - The company plans to issue technology innovation bonds, which will require shareholder approval [7][8] - A second extraordinary general meeting of shareholders is scheduled for September 15, 2025, to discuss various proposals [8]

Meeting Overview - The second meeting of the second supervisory board of the company was held on August 14, 2025, with all three supervisors present [1]. Resolutions Passed Use of Raised Funds - The supervisory board approved the proposal to provide interest-free loans from raised funds to the wholly-owned subsidiary Shenzhen Kexing Pharmaceutical for project implementation, aligning with the fundraising plan and benefiting project execution [1]. Foreign Exchange Derivative Transactions - The board approved the proposal for the company and its subsidiaries to engage in foreign exchange derivative transactions, with a limit of 75 million RMB or equivalent foreign currency, to mitigate foreign exchange risk and enhance financial stability [2]. Related Party Transaction Agreement - The board approved the signing of a supplementary agreement for related party transactions, confirming compliance with regulations and ensuring no adverse effects on the company's financial status or shareholder interests [2]. Issuance of Technology Innovation Bonds - The board approved the proposal for the company to issue technology innovation bonds, affirming that it aligns with the overall interests of the company and shareholders [3].

Group 1 - Recently, Fosun Pharma successfully issued the first long-term technology innovation bond in the private pharmaceutical sector in China, with a scale of 1 billion RMB, a term of 2 years, and a coupon rate of 2.70% [1] - The bond received enthusiastic subscriptions from various financial institutions, including bank wealth management, insurance, foreign banks, public funds, and securities firms, indicating strong market support [1][2] - The funds raised will provide strong financial support for Fosun Pharma's layout in key technology innovation areas, accelerating the transformation and implementation of innovative results [1] Group 2 - The issuance of this technology innovation bond aligns with the central government's policies to support the healthy and high-quality development of the private economy, as emphasized in recent meetings and action plans [1][2] - Fosun Pharma has been focusing on innovation as its core development driver for over 30 years, having received approvals for 12 self-developed and licensed innovative drugs since 2019, covering critical treatment areas [3] - The company aims to deepen its innovation transformation and provide high-quality, accessible products and services to patients and customers, while creating sustainable value returns for shareholders [3]

Group 1 - The capital market is undergoing profound changes, with various forces collaborating to build a stable and positive market ecosystem [1] - Regulatory authorities have systematically introduced a package of measures to stabilize the market, effectively countering unexpected external shocks and enhancing market resilience [1][3] - The total market value of A-shares has steadily increased, surpassing 100 trillion yuan by the end of June, indicating a significant rise in market activity [3] Group 2 - The new "National Nine Articles" and the "1+N" policy system for the capital market are being effectively implemented, focusing on enhancing the internal stability of the market [3] - Institutional funds, including social security, insurance, and annuities, have cumulatively net purchased over 200 billion yuan in A-shares, contributing to a virtuous cycle in the market [3] - The cash dividend total for A-share listed companies in 2024 is projected to reach 2.4 trillion yuan, a 9% increase from 2023, reflecting a growing internal drive for dividends among companies [4] Group 3 - The financing channels for technology innovation enterprises are continuously expanding, with the introduction of new listing standards for unprofitable companies on the Sci-Tech Innovation Board and the Growth Enterprise Market [4] - The merger and acquisition market is becoming increasingly active, with regulatory support for companies to engage in strategic mergers and acquisitions in emerging industries [4] - The technology innovation bond market has rapidly expanded, with 684 bonds issued, totaling 880.6 billion yuan, aimed at attracting funds to key areas of technology innovation [4]

智通财经APP获悉，近日，复星医药(02196)成功发行全国首单民营医药行业中长期科技创新债券，由招 商银行担任牵头主承销商兼簿记管理人，北京银行、浦发银行担任联席承销商，规模10亿元人民币，期 限2年，票面利率2.70%。 创立30多年来，复星医药始终以创新为核心发展驱动力，在创新药领域，自2019年以来，复星医药已累 计获批12款自主研发、许可引进的创新药和生物类似药，同时成功获得8款创新药物的中国境内商业化 权益，涵盖实体瘤、血液瘤、免疫炎症等核心治疗领域。2025年1月至5月，复星医药已有4款产品5项适 应症在中国及欧盟等多地获批，包括首个自研小分子创新药复迈宁®(芦沃美替尼片)获批上市，填补罕 见肿瘤领域空白；抗PD-1单抗斯鲁利单抗注射液成为欧盟首个获批用于广泛期小细胞肺癌(ES-SCLC)治 疗的PD-1单抗，国际化布局取得重要进展。 本期科创债获得了银行理财、保险、外资银行、公募基金、券商自营等各类型金融机构的踊跃认购，与 此同时，中债信用增进投资股份有限公司也积极参与本期债券的认购，代表监管部门为本期科创债发行 给予大力支持。本期债券募集资金将为复星医药在关键科技创新领域的布局提供有力的资金 ...

证券时报记者 叶玲珍 7月6日晚间，弘信电子（300657）公告，拟向中国银行间市场交易商协会申请注册发行2025年度第一期 科技创新债券，发行规模最高不超过5亿元，发行期限不超过3年。 弘信电子表示，若本次科技创新债券成功发行，将有利于进一步拓宽融资渠道，有效改善现金流状况， 提升流动性管理能力；与此同时，依托市场化定价机制降低综合融资成本，为公司战略发展提供中长期 资金支持。 近期，多部门打出"组合拳"支持科创债发行，各类主体发行科创债热情持续高涨。今年5月7日，中国人 民银行、中国证监会联合发布关于支持发行科技创新债券有关事宜的公告，从丰富科技创新债券产品体 系和完善科技创新债券配套支持机制等方面，对支持科技创新债券发行提出多项重要举措。随后，沪深 北交易所同步发布《关于进一步支持发行科技创新债券 服务新质生产力的通知》，从三大方面进一步 细化支持措施。 Wind数据显示，自5月份科创债相关政策落地以来，截至7月3日，全市场已发行419只科创债，发行规 模超6200亿元。 弘信电子起步于FPC（柔性印制电路板）业务，2023年开始涉足AI算力服务器的研发、设计、制造和销 售，AI算力资源服务业务等，打造 ...

Core Viewpoint - The new policy for technology innovation bonds (科创债) has led to a significant increase in issuance, with a total of 883.16 billion yuan in new bonds over the past three months, indicating a strong market response to regulatory support [1][2]. Group 1: Issuance Scale and Participants - The total issuance scale of technology innovation bonds reached 883.16 billion yuan, with financial institutions accounting for nearly 36% of this amount [1][2]. - Among the financial institutions, banks led the issuance with 230.3 billion yuan, followed by 38 securities companies that collectively issued 54.1 billion yuan [2]. - The participation of small and medium-sized institutions and private enterprises has increased, with various smaller banks and private equity firms also issuing technology innovation bonds [2]. Group 2: Characteristics of New Bonds - The average coupon rate for newly issued technology innovation bonds was 1.9282%, which is notably low compared to other credit bonds of similar ratings [3]. - A significant portion of the new bonds has a maturity of over three years, with 76.23% of the total issuance (673.22 billion yuan) falling into this category [3]. - The majority of the issuers are central and local state-owned enterprises, with 203 bonds issued by central state-owned enterprises and 369 by local state-owned enterprises [3].

证券代码：002432 证券简称：九安医疗 公告编号：2025-054 天津九安医疗电子股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 天津九安医疗电子股份有限公司（以下简称"公司"）于2025年6月3日召开 第六届董事会第二十三次会议、第六届监事会第十八次会议，审议通过了《关于 拟注册和发行中期票据及超短期融资券的议案》。同意公司向中国银行间市场交 易商协会（以下简称"交易商协会"）申请注册发行总额不超过人民币35亿元（含 容详见2025年6月5日，公司于《证券时报》、巨潮资讯网（www.cninfo.com.cn） 披露的相关公告。 公司于近日分别收到交易商协会出具的《接受注册通知书》 （中市协注〔2025〕 MTN749号和中市协注〔2025〕SCP207号），交易商协会决定接受公司科技创新 债券注册。主要内容如下： 公司将严格按照有关法律法规、交易商协会相关自律管理规定及上述通知书 的要求，充分考虑公司资金需求和市场情况，在注册有效期内择机发行中期票据 和超短期融资券，并按照《非金融企业债务融资工具注册发行规则》《非金融企 业债务融资工具 ...

Core Viewpoint - The article highlights the evolving role of financial institutions, particularly Nanjing Bank's Hangzhou branch, in supporting the growth of private enterprises in Zhejiang, transitioning from traditional lenders to partners in development and innovation [1][2]. Group 1: Financial Support for Private Enterprises - Private enterprises are crucial for high-quality development and technological innovation, yet they face significant challenges in financing [2]. - Nanjing Bank's Hangzhou branch provided over 10 million yuan in loans to Diwei II Space Technology Co., Ltd., aiding its growth during its early development phase [2]. - The bank has supported over 2,500 technology enterprises with financing exceeding 65 billion yuan, with a technology loan balance of over 9 billion yuan, addressing the financing difficulties faced by many tech firms [3]. Group 2: Innovative Financial Products - The demand for diverse funding solutions among private enterprises is increasing, necessitating innovative financial products to meet their varied needs [4]. - Nanjing Bank's Hangzhou branch successfully issued the first private enterprise technology bond in response to the new policy, with a total underwriting scale of 2.25 billion yuan for eight bonds [5]. - The bank has tailored its "Provincial Credit Loan" product to meet the urgent short-term financing needs of local manufacturing enterprises, providing over 30 million yuan through 21 loans [5]. Group 3: Building an Ecosystem - Nanjing Bank has been recognized as the "Most Satisfied Bank for Private Enterprises" in Zhejiang, reflecting its commitment to creating a collaborative ecosystem for private businesses [6]. - The bank has facilitated connections between enterprises and potential partners, exemplified by its support for Liang'an Technology, which resulted in an 800,000 yuan order [6]. - The "Xinsixiang" platform developed by the bank integrates various resources, promoting collaboration and breaking down information silos within the industry [7].

| 债券名称: | 上海银行股份有限公司2025年第一期科技创新债券 | 债券简称: | 25上海银行科创债01 | | --- | --- | --- | --- | | 债券代码: | 2520012 | 发行总额(亿元) | 50.00000000000 | | 债券期限: | 3年 | 票面年利率(%) : | 1.67 | | 计息方式: | 附息式固定利率 | 付息频率(月/次) : | 12 | | 发行日 | 20250516 | 起息日 : | 20250520 | | 债权债务登记日 : | 20250520 | 结算服务起始日: | 20250521 | | 交易流通终止日: | 20280519 | 兑付日 : | 20280520 | | 面值(元): | 100.000000 | 发行价格 | 100 元/自元面值 | 5月20日，根据中央国债登记结算有限责任公司公告，上海银行股份有限公司2025年第一期科技创新债券已完成登记注册，现将其相关要素公布如 下： （责任编辑：关婧） ...